Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

6:06 AM ET 8-K
Court & Legal Update Duke Energy Corp DUK

Duke Energy Court & Legal Update

The North Carolina Utilities Commission issued written orders approving comprehensive revenue requirement settlements for Duke Energy Carolinas and Duke Energy Progress. The orders approve a 9.8% return on equity and retail rate bases totaling approximately $43.5 billion across both entities. Revised customer rates are expected to be implemented effective January 1, 2027.

Counterparty
North Carolina Utilities Commission
4:01 PM ET 8-K
Court & Legal Update Tonix Pharmaceuticals Holding Corp. TNXP

Tonix Pharmaceuticals Holding Court & Legal Update

Tonix Pharmaceuticals filed a patent infringement lawsuit against Dr. Reddy’s Laboratories in the U.S. District Court for the District of New Jersey following a Paragraph IV certification regarding TONMYA®. The filing of the complaint triggers a statutory 30-month stay of final FDA approval for Dr. Reddy’s proposed generic version of the drug. Tonix seeks to prevent generic competition until the expiration of its Orange Book-listed patents.

Counterparty
Dr. Reddy’s Laboratories Ltd.
Term
30 months
4:21 PM ET 8-K
Court & Legal Update Pacira BioSciences, Inc. PCRX

Pacira BioSciences Court & Legal Update

The U.S. Court of Appeals for the Ninth Circuit partially reversed a lower court ruling, determining that Pacira BioSciences owes royalties to the Research Development Foundation (RDF) for EXPAREL manufactured using its 200-liter process. This decision impacts a previous $28.3 million recovery Pacira received and remands the case to the District Court to recalculate interest owed on other portions of the judgment.

Counterparty
Research Development Foundation
7:59 AM ET 8-K
Court & Legal Update Skye Bioscience, Inc. SKYE

Skye Bioscience Court & Legal Update

Skye Bioscience received a unanimous jury verdict in its favor following a retrial in the U.S. District Court for the Central District of California. The lawsuit, filed by a former employee, alleged whistleblower protection violations and retaliation related to events occurring between 2018 and 2019. The verdict clears the company of all claims, though the plaintiff retains the right to file post-trial motions or appeals.

Counterparty
Wendy Cunning
7:46 AM ET 8-K
Court & Legal Update Lamb Weston Holdings, Inc. LW

Lamb Weston Holdings Court & Legal Update

Lamb Weston, Inc., a subsidiary of Lamb Weston Holdings, Inc., entered into a $25 million settlement agreement to resolve a putative class action lawsuit regarding groundwater nitrate levels in Oregon. The settlement fund will provide property enhancements and water filtration systems for residents, with payment expected in the second half of fiscal year 2027 subject to court approval.

Counterparty
Private plaintiffs in the U.S. District Court for the District of Oregon
7:04 AM ET 8-K
Court & Legal Update Alkermes plc. ALKS

Alkermes Court & Legal Update

Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.

Counterparty
Teva Pharmaceuticals, Inc.
5:01 PM ET 8-K
Court & Legal Update Kulr Technology Group, Inc. KULR

Kulr Technology Group Court & Legal Update

KULR Technology Group filed a verified petition in the Delaware Court of Chancery under Section 205 of the DGCL to validate certain past corporate acts and its outstanding capitalization. The company identified technical failures in authorizing a 2016 name change, a 2018 increase in authorized common stock, and the designation of its Series A Preferred Stock, which it cannot ratify through standard procedures due to the disparate holding of putative shares.

Counterparty
Court of Chancery of the State of Delaware
2:02 PM ET 8-K
Court & Legal Update HyOrc Corp HYOR

HyOrc Court & Legal Update

HyOrc Corporation entered into a settlement agreement to resolve litigation in Nevada with Daniel S. McKinney and Coldway Limited, LLC. The lawsuit, which sought damages in excess of $3 million, concerned the affiliate/control classification of the plaintiffs on the company's transfer agent records. The settlement involves no monetary payment by any party and includes a mutual release of claims and the dismissal of the action with prejudice.

Counterparty
Daniel S. McKinney and Coldway Limited, LLC
4:18 PM ET 8-K
Court & Legal Update Aeries Technology, Inc. AERT

Aeries Technology Court & Legal Update

Aeries Technology entered into a settlement agreement with Sea Otter Trading, LLC to resolve outstanding obligations under a previously amended Forward Purchase Agreement. The company will pay $911,461 in exchange for the return of 145,183 Class A ordinary shares held as collateral, effectively terminating the prior transaction agreements.

Counterparty
Sea Otter Trading, LLC
6:01 AM ET 8-K
Court & Legal Update 3M Co MMM

3M Court & Legal Update

3M entered into a $7.35 billion nominal settlement ($5.8 billion present value) to resolve the vast majority of PFAS-related personal injury claims in the Aqueous Film-Forming Foam (AFFF) multi-district litigation. The settlement involves approximately 115,000 to 120,000 eligible plaintiffs and includes payments scheduled through 2034 to manage legacy litigation risks.

Counterparty
AFFF MDL Personal Injury Claimants
Term
2026-2034
6:01 AM ET 8-K
Court & Legal Update Destination Xl Group, Inc. DXLG

Destination Xl Group Court & Legal Update

The Delaware Court of Chancery granted a temporary restraining order enjoining Destination XL Group (DXL) from terminating its merger agreement with FBB Holdings I, Inc. pending further expedited proceedings. FBB filed the lawsuit to prevent DXL from exercising its right to terminate the deal if it was not consummated by the October 30, 2026 deadline. DXL intends to vigorously defend against the claims and pursue its own counterclaims.

Counterparty
FBB Holdings I, Inc.
4:05 PM ET 8-K
Court & Legal Update Enanta Pharmaceuticals Inc ENTA

Enanta Pharmaceuticals Court & Legal Update

The Unified Patent Court (UPC) of the European Union ruled that Enanta's European Patent No. EP 4 051 265 is invalid, dismissing Enanta's patent infringement action against Pfizer. The lawsuit concerned Pfizer's manufacture and sale of Paxlovid in 18 EU member states. Enanta had sought a determination of liability for infringement, but the court found the infringement action unfounded following its decision on patent validity.

Counterparty
Pfizer Inc.
4:31 PM ET 8-K
Court & Legal Update Zillow Group, Inc. ZG

Zillow Group Court & Legal Update

Zillow Group has entered into a stipulation of settlement to resolve a consolidated securities class action litigation (Jaeger v. Zillow Group, Inc.) for $212.5 million in cash. The company expects approximately $48 million of the settlement to be covered by insurance proceeds, with the remainder resolving claims related to stock purchases made between August 5, 2021, and November 2, 2021. The settlement is subject to preliminary and final court approval and contains no admission of liability or wrongdoing.

Counterparty
Jaeger v. Zillow Group, Inc., et al. (Class Action Plaintiffs)
7:46 AM ET 8-K
Court & Legal Update Beneficient BENF

Beneficient Court & Legal Update

Beneficient filed a motion to intervene in Delaware Court of Chancery litigation against HCLP Nominees, L.L.C. to invalidate approximately $130 million in purported debt and recover $211 million previously paid. The company alleges the debt was fabricated by former CEO Brad Heppner as part of a fraudulent scheme for which he was convicted in May 2026.

Counterparty
HCLP Nominees, L.L.C.

“Mr. Heppner’s fraud should not continue to burden Beneficient and its stockholders. We are executing the strategy we outlined in September and are pursuing a comprehensive resolution that allows the Company to move forward. We will continue to take the steps necessary to achieve the objectives of that strategy, including additional litigation, while we seek an acceptable consensual resolution. This filing advances our efforts by placing our claims before the Court and seeking relief from the ongoing harm Heppner is causing. Our focus remains on strengthening Beneficient’s financial position and enabling the business to realize its potential.”

James G. Silk, Chief Executive Officer
4:46 PM ET 8-K
Court & Legal Update Kinetik Holdings Inc. KNTK

Kinetik Holdings Court & Legal Update

Kinetik Holdings subsidiary EagleClaw Midstream Ventures reached a settlement with Energy Transfer to resolve a dispute regarding the expiration date of an NGL purchase agreement. The parties confirmed the agreement will terminate on December 31, 2026, while a second agreement remains subject to ongoing litigation awaiting adjudication.

Counterparty
Energy Transfer GC NGL Product Services, LLC
Term
through Dec 2026
4:42 PM ET 8-K
Court & Legal Update CV Sciences, Inc. CVSI

CV Sciences Court & Legal Update

CV Sciences has settled an arbitration case initiated in February 2025 against its former legal counsel. Under the settlement terms, the company received $500,000 and both parties have mutually released all claims against each other.

Counterparty
former legal counsel
6:02 AM ET 8-K
Court & Legal Update Phathom Pharmaceuticals, Inc. PHAT

Phathom Pharmaceuticals Court & Legal Update

Phathom Pharmaceuticals announced that the FDA has opened a public docket to solicit comments regarding legal challenges brought by BDR Pharmaceuticals against the FDA's decision to grant VOQUEZNA 10 years of New Chemical Entity (NCE) exclusivity. The litigation challenges the exclusivity period that currently protects VOQUEZNA through May 2032, and a second potential generic filer, Saba Ilac Sanayii Ve Ticaret AS, has also indicated intent to join the legal challenge.

Counterparty
BDR Pharmaceuticals, Intl. Pvt. Ltd.
5:01 PM ET 8-K
Court & Legal Update Phathom Pharmaceuticals, Inc. PHAT

Phathom Pharmaceuticals Court & Legal Update

BDR Pharmaceuticals has filed a lawsuit against the FDA challenging the agency's decision to grant Phathom's VOQUEZNA (vonoprazan) 10 years of NCE exclusivity through May 2032. BDR alleges the FDA improperly applied the GAIN Act to extend this exclusivity, which currently prevents the FDA from receiving abbreviated new drug applications (ANDAs) for generic versions of the drug. Phathom intends to take action to protect its statutory exclusivities and believes the FDA's prior ruling was correct.

Counterparty
BDR Pharmaceuticals International Pvt. Ltd.
4:15 PM ET 8-K
Court & Legal Update Onity Group Inc. ONIT

Onity Group Court & Legal Update

Onity Group Inc. filed a declaratory judgment action in federal court seeking judicial clarification of a New York mortgage servicing regulation regarding optional expedited payment fees. The company is challenging the regulation's requirement that fees be "reasonably related to the cost of rendering that service," arguing the standard is undefined and lacks fair notice. This legal action follows ongoing discussions and information requests from New York regulators concerning the company's fee practices.

Counterparty
U.S. District Court for the Northern District of New York
8:18 AM ET 8-K
Court & Legal Update Filana Therapeutics, Inc. FLNA

Filana Therapeutics Court & Legal Update

The U.S. Court of Appeals for the Fifth Circuit vacated a lower court's order that had granted class certification in a securities class action against Filana Therapeutics. The appellate court ruled that the district court misapplied legal standards regarding market efficiency and 'meme-stock' dynamics, remanding the case for further proceedings.

Counterparty
U.S. District Court for the Western District of Texas
5:15 PM ET 8-K
Court & Legal Update Curanex Pharmaceuticals Inc CURX

Curanex Pharmaceuticals Court & Legal Update

Curanex Pharmaceuticals disclosed two putative securities class action lawsuits filed in the Supreme Court of the State of New York related to its August 2025 IPO. The complaints allege material misstatements and omissions in the IPO offering documents regarding risks of stock-price manipulation and underwriter due diligence deficiencies. The company intends to defend the actions vigorously and has received extensions to respond to the complaints through late 2026.

Counterparty
Daymond Morales and Robert Lovett
4:05 PM ET 8-K
Court & Legal Update Collegium Pharmaceutical, Inc COLL

Collegium Pharmaceutical Court & Legal Update

Collegium Pharmaceutical entered into a settlement agreement with Grünenthal GmbH to resolve patent infringement litigation related to Nucynta ER. As part of the settlement, Collegium will pay $17 million to terminate a 2015 license agreement and discharge all future royalty obligations. Additionally, Grünenthal assigned certain Nucynta-related patents to Collegium and moved to dismiss the pending lawsuit.

Counterparty
Grünenthal GmbH
4:05 PM ET 8-K
Court & Legal Update ZoomInfo Technologies Inc. GTM

ZoomInfo Technologies Court & Legal Update

ZoomInfo Technologies Inc. has entered into a memorandum of understanding to settle a putative securities class action lawsuit for $44 million. The settlement, which is subject to court approval, resolves allegations that the company made false or misleading statements regarding its business and operations between 2020 and 2024. A portion of the payment is expected to be covered by insurance, though the settlement does not resolve other related derivative or direct investor lawsuits.

Counterparty
Putative class of common stock purchasers
9:00 AM ET 8-K
Court & Legal Update Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Court & Legal Update

Ultragenyx and Baylor Research Institute entered into a settlement agreement with Navinta LLC to resolve patent litigation regarding DOJOLVI® (triheptanoin). Under the agreement, Navinta is granted a non-exclusive, royalty-free license to market a generic version of the drug starting January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted.

Counterparty
Navinta LLC
7:00 AM ET 8-K
Court & Legal Update Rekor Systems, Inc. REKR

Rekor Systems Court & Legal Update

Rekor Systems filed a verified complaint in the Delaware Court of Chancery against former director Viraj Mehta, alleging a breach of his fiduciary duty of loyalty. The lawsuit relates to the company's December 2025 financing with a hedge fund and seeks compensatory damages, restitution of director compensation, and disgorgement.

Counterparty
Viraj Mehta

“Our Board took this action after months of careful investigation. Directors have a fundamental obligation to provide complete and candid information when critical financing decisions are being made. We believe the facts warrant judicial review, and we intend to pursue the Company's claims and every appropriate remedy available to protect Rekor and its shareholders.”

Robert A. Berman, Chairman and Chief Executive Officer

“This is a first step, not the end of our review. We continue to examine unusually high stock-borrow utilization rates, other unusual activity in Rekor common stock, and relevant financing and ownership matters. We will follow the evidence wherever it leads. Access to capital should not come at the expense of market integrity, corporate governance or the rights of public shareholders.”

Robert A. Berman, Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.